Benzinga · Sep 9, 2026
Jefferies Upgrades Summit Therapeutics to Buy, Raises Price Target to $25
Jefferies analyst Faisal Khurshid upgrades Summit Therapeutics (NASDAQ:SMMT) from Hold to Buy and raises the price target from $15 to $25.
SM
NASDAQ · SMMT
Summit Therapeutics Inc.
Healthcare · Biotechnology
$17.40
Down-$1.02 (-5.54%)
Updated Sep 16, 2026, 9:06 AM
SID Score
5.8/10
Composite research score
Smart Money
55/100
Neutral
- Market cap
- 13.39B
- P/E ratio
- -14.51
- Dividend yield
- 0.00%
- 52-week range
- $12.07 – $29.23
- Volume
- 5.8M
- Avg. volume
- 3.43M
Price performance
SMMT price history
1M range · 20 trading sessions · Daily adjusted prices
SMMT closed at $17.40 after 20 trading sessions, up 35.73% for the selected period.
- Last close
- $17.40
- Period change
- +35.73%
- Period low
- $12.43
- Period high
- $18.42
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $18.16 | $18.47 | $17.11 | $17.40 | 5.8M |
| Sep 14, 2026 | $18.07 | $18.83 | $17.97 | $18.42 | 7.07M |
| Sep 11, 2026 | $17.20 | $17.70 | $17.1375 | $17.55 | 4.28M |
| Sep 10, 2026 | $17.30 | $17.6208 | $16.80 | $17.00 | 4.22M |
| Sep 9, 2026 | $18.205 | $18.3216 | $17.24 | $17.54 | 4.8M |
| Sep 8, 2026 | $17.43 | $17.69 | $16.967 | $17.28 | 7.36M |
| Sep 4, 2026 | $16.935 | $17.63 | $16.80 | $17.605 | 6.95M |
| Sep 3, 2026 | $15.52 | $17.35 | $15.515 | $17.13 | 14.92M |
| Sep 2, 2026 | $14.15 | $14.72 | $14.06 | $14.60 | 3.78M |
| Sep 1, 2026 | $13.38 | $14.475 | $13.37 | $14.16 | 4.7M |
| Aug 31, 2026 | $13.51 | $13.73 | $13.44 | $13.62 | 5.43M |
| Aug 28, 2026 | $14.11 | $14.24 | $13.43 | $13.73 | 3.91M |
| Aug 27, 2026 | $14.30 | $14.65 | $13.92 | $14.33 | 4.84M |
| Aug 26, 2026 | $14.75 | $15.10 | $14.1137 | $14.23 | 11.63M |
| Aug 25, 2026 | $13.27 | $13.60 | $13.05 | $13.36 | 6.33M |
| Aug 24, 2026 | $13.08 | $13.21 | $12.22 | $12.73 | 4.39M |
| Aug 21, 2026 | $12.69 | $13.53 | $12.57 | $13.16 | 7.07M |
| Aug 20, 2026 | $13.01 | $13.02 | $12.285 | $12.43 | 6.57M |
| Aug 19, 2026 | $13.31 | $13.39 | $12.92 | $13.11 | 5.43M |
| Aug 18, 2026 | $12.60 | $13.00 | $12.53 | $12.82 | 4.6M |
Latest SMMT news
The latest Smart Investors Daily articles mentioning SMMT.
Stock researchCompany · Overview
SMMT research
Overview
Company profile and research snapshot.
Company profile
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $23.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Jefferies | Buy | — |
| Aug 26, 2026 | HC Wainwright & Co. | Neutral | — |
| Aug 25, 2026 | Bernstein | Market Perform | — |
| Aug 18, 2026 | HC Wainwright & Co. | Neutral | — |
| Aug 12, 2026 | Leerink Partners | Market Perform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 9, 2026
Summit Therapeutics shares gain after Jefferies upgrades stock to Buy
Summit Therapeutics (NASDAQ:SMMT) shares rose 5. 8% in premarket trading on Wednesday after Jefferies upgraded the biopharmaceutical company to Buy from Hold and increased its price target to $25 from $15.
Yahoo · Sep 9, 2026
Summit (SMMT) Says Akeso Reported a HARMONi-2 Overall-Survival Benefit Against Pembrolizumab
Summit Therapeutics Inc. (NASDAQ:SMMT) said partner Akeso reported a statistically significant overall survival benefit for ivonescimab monotherapy over pembrolizumab in a prespecified interim analysis of Phase 3 HARMONi-2. The randomized, double-blind study enrolled 398 patients at 55 hospitals in China with previously untreated, PD-L1-positive advanced non-small cell lung cancer without sensitizing EGFR mutations or ALK […]
Yahoo · Sep 7, 2026
Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress
Summit Therapeutics (NASDAQ:SMMT) has seen its share price surge by 28.19 percent week-on-week, primarily driven by the positive results of an ongoing clinical trial for its bispecific antibody, ivonescimab. In an updated report during the week, the listed biopharmaceutical firm said that its China-based partner, Akeso Inc., saw positive overall survival results from the randomized […]
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
